| Identification | Back Directory | [Name]
Orelabrutinib | [CAS]
1655504-04-3 | [Synonyms]
ICP-022
Orelabrutinib
Orelabrutinib USP/EP/BP
:6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-3-Pyridinecarboxamide
3-Pyridinecarboxamide, 6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)- | [Molecular Formula]
C26H25N3O3 | [MDL Number]
MFCD32184857 | [MOL File]
1655504-04-3.mol | [Molecular Weight]
427.49 |
| Chemical Properties | Back Directory | [Boiling point ]
646.3±55.0 °C(Predicted) | [density ]
1.213±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
14.80±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Orelabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase with potential antineoplastic activity. | [Uses]
Orelabrutinib has been previously approved to treat patients with relapsed or refractory (R/R) mantle cell lymphoma and R/R chronic lymphocytic leukemia/small lymphocytic lymphoma. | [Brand name]
InnobrukaTM
| [General Description]
Class: non-receptor tyrosine kinase
Treatment: CLL, SLL, MCL
Elimination half-life = 4 h
Protein binding = not reported
| [Biological Activity]
Orelabrutinib (ICP-022) is a potent, orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). | [Mechanism of action]
Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. | [target]
|
|
|
Tags:1655504-04-3
Related Product Information
|
|
191732-72-6
|
|